{"schema_version":"secwatch.filing_event.v1","accession":"0001803599-26-000003","form_type":"8-K","ticker":"CNXC","cik":"0001803599","company_name":"Concentrix Corp","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.232313+00:00","generated_at":"2026-05-16T10:41:54.956531+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Concentrix reports Q4 GAAP loss of $23.85/sh on $1.5B goodwill impairment; FY rev +2.2%","bullets":["Q4 revenue $2,552.9M (+4.3% YoY); FY revenue $9,825.8M (+2.2% YoY).","Q4 GAAP operating loss $1,382.4M includes $1,523.3M non-cash goodwill impairment; FY op loss $918.2M.","Non-GAAP diluted EPS Q4 $2.95 (vs $3.26); FY $11.22 (vs $11.42); margins declined 90-170 bps.","FY adjusted free cash flow $626.4M; cash from operations $807.0M; net debt reduced $184M.","FY returned $258M to shareholders; Q4 dividend $0.36 payable Feb 10, 2026; share repurchase auth $438.6M."],"urls":{"canonical":"https://secwatch.observer/filing/0001803599-26-000003","json":"https://secwatch.observer/filing/0001803599-26-000003.json","markdown":"https://secwatch.observer/filing/0001803599-26-000003.md","text":"https://secwatch.observer/filing/0001803599-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1803599/000180359926000003/0001803599-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1803599/000180359926000003/cnxc-20260113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:41:54.956531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}